Pathological Complete Response to Neoadjuvant Anthracycline–Taxane Chemotherapy in Stage IIIB Luminal B Her2-Negative Invasive Micropapillary Carcinoma of The Breast: A Case Report
Asian Journal of Healthy and Science · 31.07.2026 · 5 (7) · 179-196
DOI: 10.58631/ajhs.v5i7.338 ↗Kurz gefasst
Fallbericht in der Zeitschrift Asian Journal of Healthy and Science, online erschienen am 31.07.2026. Verfasst von Hizkia Robinson Junsen Lumban Gaol und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Invasive micropapillary carcinoma (IMPC) of the breast is a rare and aggressive histological subtype, accounting for approximately 1–2% of breast cancers and characterized by a high propensity for lymphovascular invasion and lymph node metastasis. Among these cases, fewer than 10% achieve a complete clinical response following neoadjuvant chemotherapy. This case report aims to provide a comprehensive clinical and pathological description of a rare case of Stage IIIB Luminal B HER2-negative invasive micropapillary carcinoma that achieved a pathological complete response (pCR) following neoadjuvant anthracycline–taxane chemotherapy and to analyze the clinicopathological and molecular factors contributing to this exceptional treatment response. This research presents a case-based analysis of a 44-year-old female patient diagnosed with locally advanced breast cancer. Clinical evaluation, imaging examinations (breast ultrasound, chest X-ray, and liver ultrasound), histopathological assessment, and immunohistochemical analysis (ER, PR, HER2, and Ki-67) were performed to establish the diagnosis, staging, and molecular subtype. Tumor growth kinetics were also estimated using tumor doubling time. The patient presented with a progressively enlarging breast mass accompanied by peau d’orange appearance and axillary lymphadenopathy. Histopathological examination confirmed grade 3 IMPC, while immunohistochemistry revealed a Luminal B HER2-negative subtype (ER/PR-positive, Ki-67: 40%). Imaging examinations showed no evidence of distant metastasis (T4bN1M0, Stage IIIB). Following AC-T neoadjuvant chemotherapy, a complete clinical response was observed, with the disappearance of the primary tumor and axillary lymph node involvement. IMPC exhibits aggressive local behavior with a high rate of nodal involvement; however, it may respond favorably to systemic therapy when appropriately managed through multimodal evaluation, accurate molecular characterization, and early detection.
Zitieren
APA
Gaol, H. R. J. L., & Rizki, K. A. (2026). Pathological Complete Response to Neoadjuvant Anthracycline–Taxane Chemotherapy in Stage IIIB Luminal B Her2-Negative Invasive Micropapillary Carcinoma of The Breast: A Case Report. Asian Journal of Healthy and Science, 5(7), 179-196. https://doi.org/10.58631/ajhs.v5i7.338
Vancouver
Gaol HRJL, Rizki KA. Pathological Complete Response to Neoadjuvant Anthracycline–Taxane Chemotherapy in Stage IIIB Luminal B Her2-Negative Invasive Micropapillary Carcinoma of The Breast: A Case Report. Asian Journal of Healthy and Science. 2026;5(7):179-196. doi:10.58631/ajhs.v5i7.338
BibTeX
@article{Gaol2026,
author = {Gaol, Hizkia Robinson Junsen Lumban and Rizki, Kiki Akhmad},
title = {Pathological Complete Response to Neoadjuvant Anthracycline–Taxane Chemotherapy in Stage IIIB Luminal B Her2-Negative Invasive Micropapillary Carcinoma of The Breast: A Case Report},
journal = {Asian Journal of Healthy and Science},
year = {2026},
volume = {5},
number = {7},
pages = {179--196},
doi = {10.58631/ajhs.v5i7.338}
}
EUVIMED